In Pax6 mutant, the boundary between strong and weak layer 5 expression is shifted rostrally. The domain of strong expression in layers 2/3 was absent throughout the neocortex.
In Pax6 mutants a domain of lower expression was not evident, but a small domain of reduced expression was apparent and restricted to a more rostral position.
Variable levels of let-7d expression within Pax6-expressing progenitors along apical-basal axis of Pax6 domain. Higher levels of expression in basal region compared to those located more apically.
Expressed in gap in expression of Pax6 and Nkx2.1 expands, partially overlapping with Pax6 expression, expanded more ventrally into Nkx2.1-positive domain.
Expressed in a narrower region, extending from the floorplate to the roofplate, whose alar domain overlaps a central portion of the diencephalic domain of Pax6 expression.
Expressed throughout much of the diencephalon, with strongest expression in alar regions overlapping the middle of the diencephalic domain of Pax6 expression (summarized in Fig 1M).
Expressed throughout much of the diencephalon, with strongest expression in alar regions overlapping the middle of the diencephalic domain of Pax6 expression (summarized in Fig 1M).
Expression was detected in the ventral thalamus. Expression overlapped with both Pax6 and Dlx2 at their caudal edges. Expression ended at the ventral/dorsal thalamus boundary.
At more caudal level, thalamocortical axon bundle does not express Lhx5. Domain expressing Lhx1, Isl1 and Pax6 but not Lhx5. Expression in putative ventral lateral geniculate nucleus.
At more caudal level, thalamocortical axon bundle does not express Lhx1. Domain expressing Lhx1, Isl1 and Pax6 but not Lhx5. Expression in putative ventral lateral geniculate nucleus.
There was a spatial dose-dependent inverse relationship between Pax6 and Sox9, with a significant negative correlation between the mRNA levels. A central to peripheral gradient was noted for Sox9 transcripts.
There was a spatial dose-dependent inverse relationship between Pax6 and Sox9, with a significant negative correlation between the mRNA levels. A central to peripheral gradient was noted for Sox9 transcripts.
There was a spatial dose-dependent inverse relationship between Pax6 and Sox9, with a significant negative correlation between the mRNA levels. A central to peripheral gradient was noted for Sox9 transcripts.
Expression was abnormal in the cortex and showed no obvious decrease on the pallial side of the pallial-subpallial boundary. Expression in subpallium continued across the boundary deep into the lateral cortex where they now overlapped high Pax6 expression.
Expressed throughout much of the diencephalon, with strongest expression in alar regions overlapping the middle of the diencephalic domain of Pax6 expression. No expression in the telencephalon (summarized in Fig 1M).
Expression was detected in V2b interneurons. There was some co-expression with Pax6 positive interneurons settled in the ventral spinal cord and not when they migrated out of the ventricular zone.
Expression was detected in V2b interneurons. There was some co-expression with Pax6 positive interneurons settled in the ventral spinal cord and not when they migrated out of the ventricular zone.
In the conditional mutant, expression was lower in the lateral area of the cortex. Co-expression with Casp3 and Pax6 indicated that increased apoptosis was mainly in intermediate progenitor cells (Eomes+) and and cells in transition stage between radial glia progenitor cells/intermediate progenitor cells (Eomes+/Pax6+).
